TheraRadar

Pharma Intelligence, Simplified

Company Portfolios →

RemeGen Co., Ltd.

32 active trials across 7 therapeutic areas

32
Active Trials
12
Phase 1
20
Phase 2
9
Phase 3
7
Therapeutic Areas
Portfolio Concentration: 81% of active trials in Oncology

Oncology

26 active / 42 total
Solid Tumor (Advanced)
5 active
14 total since 2015
NSCLC
5 active 1 Ph3
6 total since 2015
Breast Cancer
4 active
5 total since 2015
Bladder Cancer
3 active 1 Ph3
6 total since 2015
Gastric Cancer
3 active 2 Ph3
4 total since 2015
Melanoma
1 active
1 total since 2015
Renal Cell Carcinoma
1 active
1 total since 2015
Head and Neck Cancer
1 active
1 total since 2015
Colorectal Cancer
1 active
1 total since 2015
Prostate Cancer
1 active
1 total since 2015
Cervical Cancer
1 active
1 total since 2015
Ovarian Cancer
0 active
1 total since 2015

Immunology

7 active / 14 total
Ankylosing Spondylitis
4 active 3 Ph3
5 total since 2015
Lupus
2 active
5 total since 2015
Rheumatoid Arthritis
1 active 1 Ph3
4 total since 2015

Urology

1 active / 2 total
Erectile Dysfunction
1 active
2 total since 2015

Metabolic

1 active / 2 total
Diabetic Complications
1 active 1 Ph3
2 total since 2015

Cardiovascular

1 active / 2 total
Myocardial Infarction
1 active
2 total since 2015

CNS

1 active / 1 total
Multiple Sclerosis
1 active
1 total since 2015

Ophthalmology

0 active / 2 total
Age-Related Macular Degeneration
0 active
2 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)